ECCO Guidelines on Inflammatory Bowel Disease and Malignancies

Gordon, Hannah; Biancone, Livia; Fiorino, Gionata; Κατσάνος, Κωνσταντίνος; Kopylov, Uri; Sulais, Eman Al; Axelrad, Jordan E.; Balendran, Karthiha; Burisch, Johan; Ridder, Lissy de; Derikx, Lauranne; Ellul, Pierre; Greuter, Thomas; Iacucci, Marietta; Jiang, Caroline Di; Kapizioni, Christina; Karmiris, Konstantinos; Kirchgesner, Julien; Laharie, David; Ortega, Triana Lobatón; Molnár, Tamás; Noor, Nurulamin M; Rao, Rohit; Saibeni, Simone; Scharl, Michael; Vavricka, Stephan R.; Raine, Tim

doi:10.1093/ecco-jcc/jjac187

Cited by 89 publications

(116 citation statements)

References 307 publications

(379 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the CESAME study, a prospective observational cohort, the patients with long-standing extensive colitis had an increased CRC risk 7-fold compared to the general population (SIR 7.0; 95% CI: 4.4–10.5), whereas SIRs was 2.2 (95% CI: 1.5–3.0) for all IBD patients and 1.1 (95% CI: 0.6–1.8) in patients without long-standing extensive colitis [ 22 ]. Of note, the risk increases significantly 8–10 years after diagnosis or when dysplasia is detected on colonic biopsies [ 23 ]. In addition, co-existing primary sclerosing cholangitis (PSC) has a significantly increased CRC risk, particularly in patients with UC (HR: 2.43) [ 24 ].…”

Section: Inflammation-related Cancer In Patients With Ibdmentioning

confidence: 99%

“…In summary, based on available evidence, there is no additional increased risk of new or recurrent cancer with thiopurine, MTX, or biologic therapy, including anti-TNF and VDZ, in IBD patients with a history of previous cancer beyond the known risk in general IBD patients (without previous cancer). However, it is important to note that most data are from patients starting thiopurine or anti-TNF more than 5 years after cancer resolution and in patients with a low risk of cancer recurrence [ 23 , 106 ].…”

Section: Management Of Ibd Therapy In Patients With a History Of Prev...mentioning

confidence: 99%

“…For IBD patients with a current diagnosis or active cancer, thiopurines should be withdrawn [ 23 , 101 , 106 ]. Given a potential risk related to mutations in tumor suppressor genes, T-cell suppression, and bone marrow suppression [ 110 ].…”

Section: Management Of Ibd Therapy In Patients With Current or Active...mentioning

confidence: 99%

“…Thiopurines should be withheld during the treatment of cancer or until the cancer is controlled. For patients with cancers or pre-neoplastic lesions that are considered to be at low risk of recurrence and that have been successfully removed endoscopically or surgically, such as non-aggressive basal cell carcinoma, cervical dysplasia, or sporadic colonic polyps, thiopurines can be continued with closed monitoring for cancer surveillance [ 23 ].…”

Section: Management Of Ibd Therapy In Patients With Current or Active...mentioning

confidence: 99%

“…However, statistical analysis was limited by the small sample size and heterogeneity of the patients studied [ 111 ]. There are insufficient data on whether MTX has a negative impact on cancer progression or prognosis [ 23 ].…”

Section: Management Of Ibd Therapy In Patients With Current or Active...mentioning

confidence: 99%

See 4 more Smart Citations

The Optimal Management of Inflammatory Bowel Disease in Patients with Cancer

Wetwittayakhlang

Tselekouni

Al-Jabri

et al. 2023

JCM

View full text Add to dashboard Cite

Patients with inflammatory bowel disease (IBD) have an increased risk of cancer secondary to chronic inflammation and long-term use of immunosuppressive therapy. With the aging IBD population, the prevalence of cancer in IBD patients is increasing. As a result, there is increasing concern about the impact of IBD therapy on cancer risk and survival, as well as the effects of cancer therapies on the disease course of IBD. Managing IBD in patients with current or previous cancer is challenging since clinical guidelines are based mainly on expert consensus. Evidence is rare and mainly available from registries or observational studies. In contrast, excluding patients with previous/or active cancer from clinical trials and short-term follow-up can lead to an underestimation of the cancer or cancer recurrence risk of approved medications. The present narrative review aims to summarize the current evidence and provide practical guidance on the management of IBD patients with cancer.

show abstract

Section: Inflammation-related Cancer In Patients With Ibdmentioning

confidence: 99%

Section: Management Of Ibd Therapy In Patients With a History Of Prev...mentioning

confidence: 99%

Section: Management Of Ibd Therapy In Patients With Current or Active...mentioning

confidence: 99%

Section: Management Of Ibd Therapy In Patients With Current or Active...mentioning

confidence: 99%

Section: Management Of Ibd Therapy In Patients With Current or Active...mentioning

confidence: 99%

See 3 more Smart Citations

The Optimal Management of Inflammatory Bowel Disease in Patients with Cancer

Wetwittayakhlang

Tselekouni

Al-Jabri

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

Utilization of Biologic Disease‐Modifying Antirheumatic Therapy in Patients With Rheumatoid Arthritis and Recently Diagnosed Breast Cancer

Ruiz,

Lei,

et al. 2024

Arthritis Care & Research

View full text Add to dashboard Cite

ObjectiveBiologic disease modifying antirheumatic drugs (bDMARD) are immunosuppressants, and there have been concerns that they might impact tumor immunity in cancer patients with rheumatoid arthritis (RA). The purpose of this study was to describe the utilization trends of bDMARD in patients with RA after breast cancer (BC) diagnosis.MethodsWe performed a retrospective cohort study of adults with RA and BC (2008 onwards) from: Optum's de‐identified Clinformatics® Data Mart Database (CDM), the Surveillance, Epidemiology, and End Results Program (SEER)‐Medicare and the Texas Cancer Registry (TCR)‐Medicare databases. We evaluated bDMARD utilization trends during the first 3 years after BC. We conducted multivariable logistic regression to evaluate the association of utilization with patient characteristics.Results1,412 patients were identified in CDM and 1,439 patients in SEER/TCR‐Medicare. During the three months before BC diagnosis 28.2% (CDM) and 26.9% (SEER/TCR‐Medicare) patients had received bDMARD. Within the first three years after diagnosis 24.1% (CDM) and 26.4% (SEER/TCR‐Medicare) were receiving bDMARD. About 70% of the patients in the two cohorts received glucocorticoids with no significant time trend increases. The largest predictor of bDMARD use was prior use before BC: odds ratio (OR):27.15,95% confidence interval (CI):19.29‐38.19 (CDM), OR:18.98,95%CI:13.72‐26.26 (SEER/TCR). Distant and regional BC compared to in situ/localized were also associated with lower bDMARD in SEER/TCR‐Medicare (OR:0.54,95%CI:0.36‐0.82; OR:0.31,95%CI:0.13‐0.77).ConclusionThe use of tumor necrosis factor inhibitors (TNFi) and other bDMARD in patients with RA and recent BC has not increased since 2008. Glucocorticoids use remained high. Largest predictor of bDMARD utilization was prior use before BC.image

show abstract

Recent advances in bacteria‐based platforms for inflammatory bowel diseases treatment

Lu,

Shen,

et al. 2024

Exploration

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a recurring chronic inflammatory disease. Current treatment strategies are aimed at alleviating clinical symptoms and are associated with gastrointestinal or systemic adverse effects. New delivery strategies are needed for the treatment of IBD. Bacteria are promising biocarriers, which can produce drugs in situ and sense the gut in real time. Herein, we focus on recent studies of engineered bacteria used for IBD treatment and introduce the application of engineered bacteria in the diagnosis. On this basis, the current dilemmas and future developments of bacterial delivery systems are discussed.

show abstract

ECCO Guidelines on Inflammatory Bowel Disease and Malignancies

Cited by 89 publications

References 307 publications

The Optimal Management of Inflammatory Bowel Disease in Patients with Cancer

The Optimal Management of Inflammatory Bowel Disease in Patients with Cancer

Utilization of Biologic Disease‐Modifying Antirheumatic Therapy in Patients With Rheumatoid Arthritis and Recently Diagnosed Breast Cancer

Recent advances in bacteria‐based platforms for inflammatory bowel diseases treatment

Contact Info

Product

Resources

About